Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development

Fineline Cube Jun 8, 2026
Company Deals

Everest Medicines Licenses LNZ100 Presbyopia Treatment from Corxel for Greater China – Aceclidine-Based Eye Drop Offers Novel Miotic Mechanism

Fineline Cube Jun 8, 2026
Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026
Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026
Company Deals

Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines – Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases

Fineline Cube Jun 5, 2026
Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026
Company Drug

Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population

Fineline Cube Jun 8, 2026
Company Drug

Novo Nordisk’s Zenagamtide (Amycretin) Delivers 1.71% A1C Reduction and 14.6% Weight Loss in Phase 2 Type 2 Diabetes Trial – Dual GLP-1/Amylin Agonist Advances to Phase 3

Fineline Cube Jun 8, 2026
Company Drug

Biogen’s BIIB080 Receives FDA Fast Track Designation for Alzheimer’s

Fineline Cube Apr 3, 2025

US-based Biogen Inc. (NASDAQ: BIIB) announced that it has received Fast Track designation (FTD) from...

Policy / Regulatory

NMPA Reduces Influenza Vaccine Batch Release Time to 45 Working Days

Fineline Cube Apr 3, 2025

The National Medical Products Administration (NMPA) has issued a notification reducing the time limit for...

Company Deals

Pfizer and Flagship Pioneering Collaborate on AI-Driven Drug Development

Fineline Cube Apr 3, 2025

US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has entered into a collaboration agreement with Flagship...

Company Deals

Nurix Therapeutics Expands Sanofi Partnership with Undisclosed TPD Program

Fineline Cube Apr 3, 2025

US-based targeted protein degradation (TPD) specialist Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced an expanded partnership...

Company

Jiangxi Rimag Lists CT Chest Lesion Data on Shanghai Data Exchange

Fineline Cube Apr 3, 2025

China-based medical imaging expert Jiangxi Rimag Group Co., Ltd (HKG: 2522) has announced the successful...

Company Drug

Novartis’ Fabhalta Approved in China for C3 Glomerulopathy

Fineline Cube Apr 3, 2025

Novartis’ (NYSE: NVS) Fabhalta (iptacopan) has received approval from China’s National Medical Products Administration (NMPA)...

Company Drug

Shionogi Submits Rolling NDA for Ensitrelvir in US for COVID-19 Prophylaxis

Fineline Cube Apr 2, 2025

Shionogi announced on April 1, 2025, the initiation of a rolling New Drug Application (NDA)...

Policy / Regulatory

China’s National Health Commission Outlines Key Tasks for Primary Healthcare Reform in 2025

Fineline Cube Apr 2, 2025

The General Office of China’s National Health Commission has issued a notice outlining key tasks...

Company Drug

Pfizer Expands Abrysvo RSV Vaccine Indication to Include Ages 18-59 in EU

Fineline Cube Apr 2, 2025

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has amended the marketing...

Company Drug Legal / IP

AccurEdit’s ARTbase-A1 Base Editor Authorized by USPTO

Fineline Cube Apr 2, 2025

On April 2, 2025, China-based AccurEdit Therapeutics (Suzhou) Co., Ltd., a specialist in gene editing...

Company Deals

Organon Acquires U.S. Rights to TOFIDENCE from Biogen

Fineline Cube Apr 2, 2025

Organon (NYSE: OGN) announced today that it has acquired regulatory and commercial rights in the...

Company Drug

Zhifei Bio’s Trivalent Influenza Vaccine Approved for Clinical Trials in China

Fineline Cube Apr 2, 2025

Zhifei Biological (SHE: 300122) announced on April 1, 2025, that its subsidiary Zhifei Longcom has...

Company Deals

ChemPartner Plans Share Issuance to Raise Up to 316.3 Million Yuan

Fineline Cube Apr 2, 2025

On April 2, 2025, ChemPartner Pharmatech (SHE: 300149) announced plans to issue shares to a...

Company Deals Medical Device

Peijia Medical and DSM-Firmenich Collaborate on Polymer Heart Valve Innovation

Fineline Cube Apr 2, 2025

Peijia Medical Technology (Suzhou) Co., Ltd. today held a strategic innovation cooperation signing ceremony and...

Company Drug

Henlius and Organon’s HLX11 Biosimilar Clears EMA Validation Hurdle

Fineline Cube Apr 2, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) and Organon (NYSE: OGN) announced that the European Medicines...

Company Drug

Huadong Medicine’s Semaglutide Injection Accepted for Review by China’s NMPA

Fineline Cube Apr 2, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA)...

Company Deals

Medtronic Partners with Methinks AI to Enhance Stroke Care in Emerging Markets

Fineline Cube Apr 2, 2025

Medtronic announced a strategic partnership with Methinks AI, a leading provider of AI-driven radiological triage...

Company Drug

Hengrui Pharmaceuticals Secures Clinical Trial Approval for HRS-9813 in IPF

Fineline Cube Apr 2, 2025

Hengrui Pharmaceuticals (SHA: 600276) announced on April 1, 2025, that its HRS-9813 capsule has received...

Company Medical Device

Sino Medical Sciences Secures Malaysian Approval for Coronary Balloon Catheter

Fineline Cube Apr 1, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced receiving marketing approval in Malaysia...

Company Drug

Luye Pharma’s Weekly Rivastigmine Patch Approved in Japan for Alzheimer’s

Fineline Cube Apr 1, 2025

China-based Luye Pharma Group (HKG: 2186) announced that it has received marketing approval from Japan’s...

Posts pagination

1 … 197 198 199 … 679

Recent updates

  • Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population
  • Novo Nordisk’s Zenagamtide (Amycretin) Delivers 1.71% A1C Reduction and 14.6% Weight Loss in Phase 2 Type 2 Diabetes Trial – Dual GLP-1/Amylin Agonist Advances to Phase 3
  • Oricell Therapeutics Receives NMPA Clearance for World’s First GPC3-Targeted CAR-T Therapy in Advanced Liver Cancer – Ori-C101 Enters Confirmatory Phase II
  • Boehringer Ingelheim’s Survodutide Dual Agonist Achieves 34% Visceral Fat Reduction and 60% MASLD Resolution in Phase III ADA 2026 Data
  • Eli Lilly’s Retatrutide Delivers Unprecedented 28.3% Weight Loss and Resolves Multiple Obesity Comorbidities in Phase III TRIUMPH-1 and TRANSCEND-T2D-1 Trials
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population

Company Drug

Novo Nordisk’s Zenagamtide (Amycretin) Delivers 1.71% A1C Reduction and 14.6% Weight Loss in Phase 2 Type 2 Diabetes Trial – Dual GLP-1/Amylin Agonist Advances to Phase 3

Company Drug

Oricell Therapeutics Receives NMPA Clearance for World’s First GPC3-Targeted CAR-T Therapy in Advanced Liver Cancer – Ori-C101 Enters Confirmatory Phase II

Company Drug

Boehringer Ingelheim’s Survodutide Dual Agonist Achieves 34% Visceral Fat Reduction and 60% MASLD Resolution in Phase III ADA 2026 Data

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.